CAROLINA GUTIERREZ to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications CAROLINA GUTIERREZ has written about Xenograft Model Antitumor Assays.
Connection Strength
0.217
-
A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013 Aug 01; 73(15):4885-97.
Score: 0.086
-
Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nat Med. 2018 05; 24(4):505-511.
Score: 0.030
-
HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clin Cancer Res. 2017 Sep 01; 23(17):5123-5134.
Score: 0.028
-
Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Mol Cancer Res. 2016 05; 14(5):470-81.
Score: 0.026
-
Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy. Clin Cancer Res. 2015 Sep 01; 21(17):3995-4003.
Score: 0.025
-
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res. 2014 Sep 11; 16(5):430.
Score: 0.023